Toxicon : official journal of the International Society on Toxinology · 2025
Clinical performance of Botulinum Toxin injections in the treatment of bruxism: A retrospective study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mehri Turki Imen
Аннотация
CONTEXT: The effectiveness of botulinum toxin (BTX) in treating bruxism is recognised and well-established. However, it is often recommended in cases of severe bruxism.
OBJECTIVES: This study aims to highlight the performance of trigger points (TrPs) released with BTX injections at an early stage of bruxism while providing an overview of its analgesic effect.
METHODS: 67 patients who suffered from bruxism between 2009 and 2015 and who recovered completely after injection sessions. Patients were divided into two groups based on bruxism duration. The main outcomes were pain relief, injection sessions, required doses, and recovery duration between two consecutive sessions. The treatment was stopped when bruxism disappeared.
RESULTS: Out of all the patients who experienced long-standing symptoms, 70,3 % were given high doses of toxin, while only 16,67 % of patients with recent bruxism received similar doses. Long-standing bruxism required more injection sessions than recent bruxism where the time to recurrence between sessions was longer. The follow-up varied from 16 to 55 months.
CONCLUSION: Our study highlights promising and reliable results in treating bruxism and myofascial pain using botulinum toxin, particularly in trigger points, where the earlier it is started, the lower the doses and the better the effect in the long term.
OBJECTIVES: This study aims to highlight the performance of trigger points (TrPs) released with BTX injections at an early stage of bruxism while providing an overview of its analgesic effect.
METHODS: 67 patients who suffered from bruxism between 2009 and 2015 and who recovered completely after injection sessions. Patients were divided into two groups based on bruxism duration. The main outcomes were pain relief, injection sessions, required doses, and recovery duration between two consecutive sessions. The treatment was stopped when bruxism disappeared.
RESULTS: Out of all the patients who experienced long-standing symptoms, 70,3 % were given high doses of toxin, while only 16,67 % of patients with recent bruxism received similar doses. Long-standing bruxism required more injection sessions than recent bruxism where the time to recurrence between sessions was longer. The follow-up varied from 16 to 55 months.
CONCLUSION: Our study highlights promising and reliable results in treating bruxism and myofascial pain using botulinum toxin, particularly in trigger points, where the earlier it is started, the lower the doses and the better the effect in the long term.